Cognitive Function After Treatment of Primary CNS Malignancy

Overview

Información sobre este estudio

The purpose of this study is to evaluate cognitive function and to determine neurocognitive assessment using a select CogState test battery in patients with primary intracranial malignancies receiving photon- or proton-based cranial irradiation with curative intent.

 

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Age ≥ 4 years.
  • Able to use computer for assessment battery.
  • Receiving cranial photon- or proton-based radiation for primary central nervous system malignancy.
  • Histological or radiologic confirmation of intracranial disease.
  • ECOG Performance Status (PS) 0-2, Karnofsky PS 60-100, or Lansky/Play PS for Children 60-100.
  • Ability to complete clinical quality of life questionnaire(s) by themselves or with assistance.
  • Demonstrates the capacity to sign informed consent.
  • Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136*, **
    • * Patients do not need to agree to Registry blood draw.
    • **Patients at Mayo Clinic  Florida and Arizona can be enrolled without concurrent Registry consent.   

Exclusion Criteria:

  • Patients with WHO Grade IV astrocytoma or glioblastoma tumors.
    • Note: A patient with Grade IV tumors of other histology can participate in the study if they meet all other criteria.
    • Note: Diffuse Astrocytomas with molecular  features of glioblastoma are acceptable on study
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,  symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Any prior intracranial radiation.
  • Patients receiving Gamma Knife radiosurgery.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Nadia Laack, M.D.

Cerrado para la inscripción

Contact information:

Brianna Tranby M.A.

(507) 284-0276

Tranby.Brianna@mayo.edu

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Daniel Trifiletti, M.D.

Cerrado para la inscripción

Contact information:

Anna Harrell M.P.H.

Harrell.Anna@mayo.edu

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Sujay Vora, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20425261

Mayo Clinic Footer